可卡因使用伴胸痛患者心肌梗死患病率:系统评价与荟萃分析
该系统评价与荟萃分析检索PubMed、EMBASE和Scopus至2021年2月18日,纳入16项急诊科研究共3269例可卡因相关胸痛患者。合并AMI患病率为4.7%(95%CI 0.8-23),低危患者为1.1%(95%CI 0.2-5),混合风险患者为7.7%(95%CI 5-11)。CAD、HTN、DM、HLD病史与AMI正相关。作者建议对这类患者进行风险分层并据此处理。
要点
- 可卡因相关胸痛患者合并AMI的总体患病率为4.7%(95%CI 0.8-23),异质性高(I²=84%)。
- 作者定义的低危患者AMI患病率仅1.1%(95%CI 0.2-5),混合风险患者为7.7%(95%CI 5-11)。
- CAD病史(Corr. Coeff. 5.6,96%CI 2.3-8.7)、HTN(2.9,95%CI 0.9-4.9)、DM(8.0,95%CI 2.4-14)、HLD(5.9,95%CI 2.4-9)与AMI正相关。
- 异质性来源包括作者定义的患者风险、研究设计、发表年份和研究样本量。
- 临床应对可卡因相关胸痛患者进行风险分层并据此处理,高危患者AMI患病率仍较高。
适用人群与场景
- 因胸痛就诊于急诊科且 concurrent 可卡因使用的患者(CPCC)。
- 排除:非英文研究、非急诊科开展的研究、仅报告阳性病例而未报告AMI发生率者。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 原文未提及
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:系统评价与荟萃分析;纳入16项研究,共3269例患者;检索PubMed、EMBASE、Scopus至2020年5月18日,2021年2月18日更新。
- 主要终点:可卡因相关胸痛患者AMI合并患病率4.7%(95%CI 0.8-23),I²=84%。
- 亚组:低危患者AMI患病率1.1%(95%CI 0.2-5),混合风险患者7.7%(95%CI 5-11)。
- 荟萃回归:CAD病史Corr. Coeff. 5.6(96%CI 2.3-8.7)、HTN 2.9(95%CI 0.9-4.9)、DM 8.0(95%CI 2.4-14)、HLD 5.9(95%CI 2.4-9)与AMI正相关。
- 异质性来源:作者定义的患者风险、研究设计、发表年份、研究样本量。
证据类型、等级与局限
- 证据类型:系统评价与荟萃分析(纳入研究的设计未在摘要中逐一说明)。
- 局限:异质性高(I²=84%);仅纳入英文研究;排除非急诊科研究及仅报告阳性病例的病例报告;原文未给出证据等级或推荐强度。
对床旁实践的改变
- 对急诊科可卡因相关胸痛患者应进行风险分层:低危患者AMI患病率低(1.1%),混合风险患者较高(7.7%)。
- CAD、HTN、DM、HLD病史与AMI正相关,评估时应纳入这些因素。
- 原文未提供具体处置方案或药物剂量,不能据此改变具体治疗流程。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Cocaine abuse is a public health burden. Cocaine is known to cause vasospasm and acute myocardial infarction (AMI). The prevalence of AMI in patients presenting with chest pain and concurrent cocaine use (CPCC) varies among studies. We performed a systemic review and meta-analysis to assess the current literature for the prevalence of AMI in patients with CPCC.
METHODS: We performed a literature search of PubMed, EMBASE, and Scopus from its beginning to May 18, 2020 and updated this search on February 18, 2021. Full-text studies that assessed the primary outcome (AMI) specifically among patients with CPCC who presented to the emergency department (ED) were included. We excluded studies that were not in English, did not take place in the ED, and case reports, which only reported positive cases and not incidence of AMI. Random effect meta-analysis was performed to assess the prevalence of primary outcome and to examine correlations between risk factors and AMI. Heterogeneity was assessed by I-square value. We also performed subgroup analysis to identify potential sources of heterogeneity.
RESULTS: We identified 2178 studies and screened 102 full-text studies to include 16 studies (3269 patients) in our final analysis. The pooled prevalence of AMI was 4.7% (95% CI 0.8-23), I-square of 84%. However, rates among studies of low risk patients were lower (1.1% 95% CI 0.2-5) compared to studies of mixed risk patients (7.7%, 95% 5-11). A meta-regression was used to look at correlation between risk factors and AMI and found that AMI was positively correlated in patients with a history of CAD (correlation coefficient [Corr. Coeff.] 5.6, 96% CI 2.3-8.7), HTN (Corr. Coeff. 2.9, 95% CI 0.9-4.9), DM (Corr. Coeff. 8.0, 95% CI 2.4-14), HLD (Corr. Coeff. 5.9, 95% CI 2.4, 9). Sources of potential heterogeneity included patients' risk as defined by the authors, study designs, publication year, and study sample size.
CONCLUSION: The overall prevalence of AMI and death among patients with cocaine-associated chest pain was relatively low, although high risk patients were still associated with high prevalence of AMI. Clinicians should consider risk-stratify these patients and treat them accordingly.
参考来源
- Wang J, Patel PS, Andhavarapu S, et al. Prevalence of myocardial infarction among patients with chest pain and cocaine use: A systematic review and meta-analysis. Am J Emerg Med. 2021. PMID: 34482129. doi:10.1016/j.ajem.2021.08.024
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。